2. Signaling Pathways
  3. Epigenetics
  4. Epigenetic Reader Domain
  5. CECR2 Isoform

CECR2

CECR2 is a chromatin-remodeling complex component involved in transcriptional regulation[1]. It plays a critical role in maintaining genomic stability and epigenetic control during development and cellular differentiation[2]. The CECR2 bromodomain has been identified as a promising therapeutic target due to its involvement in recognizing acetylated histone marks, which are key epigenetic signals in gene activation[3]. A selective inhibitor of the CECR2 bromodomain, GNE-886, has been developed and shown to modulate gene expression profiles in cancer cells by disrupting chromatin interactions[4]. This compound demonstrates potent activity against CECR2-dependent pathways, offering potential for targeted therapy in diseases with aberrant epigenetic regulation[5]. Recent studies using high-throughput screening and structural biology have provided insights into the molecular mechanisms underlying CECR2 function and inhibition[6]. These findings highlight the importance of CECR2 in both physiological and pathological contexts, particularly in oncology and developmental disorders[7].

CECR2 관련 제품 (4):

Cat. No. 상품명 효과 Purity
  • HY-110374
    NVS-CECR2-1
    		Inhibitor 99.40%
    NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC50=47 nM; KD=80 nM). NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism. NVS-CECR2-1 is a chemical probe.
  • HY-112610
    CF53
    		Inhibitor 99.81%
    CF53 is a highly potent, selective and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2.2 nM and an IC50 of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins with high affinities, very selective over non-BET bromodomain-containing proteins. CF53 shows potent anti-tumor activity both in vitro and in vivo.
  • HY-114205A
    TP-238 hydrochloride
    		Inhibitor ≥99.0%
    TP-238 hydrochloride is a potent and selective dual CECR2/BPTF probe with IC50 values of 30 nM and 350 nM, respectively. TP-238 hydrochloride also inhibits BRD9 with a pIC50 of 5.9 and is less active against other 338 kinases.
  • HY-114205
    TP-238
    		Inhibitor
    TP-238 is a potent and selective dual CECR2/BPTF probe with IC50 values of 30 nM and 350 nM, respectively. TP-238 also inhibits BRD9 with a pIC50 of 5.9 and is less active against other 338 kinases.